Category: Medical Professional News

Adelaide Event: Menopause Essentials Update – 4th June

Menopause Essentials Update ABOUT This update on Menopause is aimed at GP’s, gynaecologists, endocrinologists and other health professionals who are seeking a comprehensive review… Continue Reading →

Read more

What is HSDD? – Patient Resource

Patient Resource – Website What is HSDD? Hypoactive sexual desire dysfunction (HSDD) is an extremely common medical condition that causes distress resulting from a… Continue Reading →

Read more

IMS: Sexual wellbeing after menopause

Patient Support Material: Free yourself and embrace positive sexual wellbeing Sexual health is a state of physical, emotional, mental and social wellbeing related to… Continue Reading →

Read more

Share your opinions as a woman with POI/ Premature menopause.

International POI guideline update survey What matters for you? A 10 minute scoping survey for women or for health professionals: An international collaboration between the European… Continue Reading →

Read more

Jean Hailes: National Women’s Health Survey

National Women’s Health Survey Welcome to Jean Hailes survey This survey was developed by Jean Hailes for Women’s Health and a team of experts…. Continue Reading →

Read more

Monash University: Bone Density Study

A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →

Read more

AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women

Lawley Pharmaceuticals  has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →

Read more

Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →

Read more

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →

Read more

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →

Read more